PROS1 and COVID-19: Furthermore, a recombinant adenovirus Type 5 vectored COVID-19 vaccine (Ad5-nCoV), which expresses S protein of SARS-CoV-2, has been developed by CanSino Biologics and has entered Phase II clinical trials (Figure 2) [63].